Freeline Therapeutics

Biotechnology company focused on developing liver directed gene therapies for a range of diseases

Ticker

FRLN.NASDAQ

Trh

Kapitalizace

$276

Rok založení

2015

Potenciál růstu

96.38%

Uzávěrka

8/20/2020

Datum IPO

8/6/2020

Cena umístění

$18

Ziskovost

-3.61%

O společnosti

Total Funding

$302.1M

Freeline is a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases. The Company has clinical programs in Hemophilia B and Fabry disease, as well as preclinical programs in Gaucher disease and Hemophilia A. Freeline is headquartered in the UK and has operations in Germany and the US.

Number of employees

101 - 250

Headquarters

Stevenage, Herefordshire, United Kingdom